Jérôme Lemonnier

3.3k total citations
64 papers, 1.6k citations indexed

About

Jérôme Lemonnier is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Jérôme Lemonnier has authored 64 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 39 papers in Oncology, 27 papers in Pulmonary and Respiratory Medicine and 26 papers in Cancer Research. Recurrent topics in Jérôme Lemonnier's work include Advanced Breast Cancer Therapies (25 papers), Breast Cancer Treatment Studies (22 papers) and Cancer Treatment and Pharmacology (12 papers). Jérôme Lemonnier is often cited by papers focused on Advanced Breast Cancer Therapies (25 papers), Breast Cancer Treatment Studies (22 papers) and Cancer Treatment and Pharmacology (12 papers). Jérôme Lemonnier collaborates with scholars based in France, Belgium and Switzerland. Jérôme Lemonnier's co-authors include Pierre J. Marie, Joseph Caverzasio, Eric Haÿ, Jérôme Guicheux, Chafik Ghayor, Olivia Fromigué, Abderrahim Lomri, Philippe Delannoy, Dominique Modrowski and Gaby Palmer and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and Cancer.

In The Last Decade

Jérôme Lemonnier

62 papers receiving 1.5k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jérôme Lemonnier France	19	941	514	348	286	196	64	1.6k
David Cappellen France	21	1.6k 1.7×	545 1.1×	165 0.5×	277 1.0×	177 0.9×	50	2.3k
Kenneth R. Shroyer United States	22	860 0.9×	350 0.7×	186 0.5×	229 0.8×	210 1.1×	33	1.5k
Lior Zilberberg United States	20	824 0.9×	198 0.4×	641 1.8×	275 1.0×	402 2.1×	24	1.7k
Christof Hofele Germany	24	729 0.8×	539 1.0×	214 0.6×	263 0.9×	244 1.2×	47	1.6k
Natacha Entz‐Werlé France	19	588 0.6×	428 0.8×	137 0.4×	426 1.5×	441 2.3×	83	1.5k
Awad Jarrar United States	14	651 0.7×	736 1.4×	79 0.2×	350 1.2×	265 1.4×	26	1.5k
Gian Paolo Tonini Italy	25	947 1.0×	337 0.7×	182 0.5×	523 1.8×	119 0.6×	88	1.8k
Jin Sung Jang United States	24	1.0k 1.1×	516 1.0×	122 0.4×	420 1.5×	324 1.7×	49	1.7k
Rebecca Sowers United States	19	801 0.9×	562 1.1×	115 0.3×	270 0.9×	460 2.3×	24	1.5k
Ann‐Marie Baker United Kingdom	17	764 0.8×	630 1.2×	132 0.4×	404 1.4×	201 1.0×	44	1.7k

Countries citing papers authored by Jérôme Lemonnier

Since Specialization

Citations

This map shows the geographic impact of Jérôme Lemonnier's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jérôme Lemonnier with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jérôme Lemonnier more than expected).

Fields of papers citing papers by Jérôme Lemonnier

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jérôme Lemonnier. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jérôme Lemonnier. The network helps show where Jérôme Lemonnier may publish in the future.

Co-authorship network of co-authors of Jérôme Lemonnier

This figure shows the co-authorship network connecting the top 25 collaborators of Jérôme Lemonnier. A scholar is included among the top collaborators of Jérôme Lemonnier based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jérôme Lemonnier. Jérôme Lemonnier is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Licaj, Idlir, Elodie Coquan, Tienhan Sandrine Dabakuyo‐Yonli, et al.. (2023). Baseline quality of life and chemotherapy toxicities in patients with early breast cancer. Cancer. 129(7). 1085–1095. 4 indexed citations

Bras, Alicia Le, Yazid Belkacémi, C. Bourgier, et al.. (2023). Economic evaluation and budget-impact of accelerated partial breast irradiation (APBI) versus standard or hypofractionated whole breast irradiation (WBI) in postmenopausal women with early-stage breast cancer. Results from the French SHARE randomized trial. Radiotherapy and Oncology. 187. 109818–109818. 1 indexed citations

Berger, Frédérique, Suzette Delaloge, Anne‐Claire Hardy‐Bessard, et al.. (2022). Randomised, open-label, multicentric phase III trial to evaluate the safety and efficacy of palbociclib in combination with endocrine therapy, guided by ESR1 mutation monitoring in oestrogen receptor-positive, HER2-negative metastatic breast cancer patients: study design of PADA-1. BMJ Open. 12(3). e055821–e055821. 26 indexed citations

Bachelot, Thomas, Florence Dalenc, Sylvie Chabaud, et al.. (2021). Efficacy of everolimus in patients with HR+/HER2- high risk early stage breast cancer. Annals of Oncology. 32(4). 574–575. 8 indexed citations

Delaloge, Suzette, Sylvain Dureau, Véronique D’Hondt, et al.. (2021). 63O Letrozole and palbociclib versus third generation chemotherapy as neoadjuvant treatment in luminal breast cancer: Survival results of the UNICANCER-NeoPAL study. Annals of Oncology. 32. S48–S48. 1 indexed citations

Gal, Jocelyn, G. Milano, Patrick Brest, et al.. (2020). VEGF-Related Germinal Polymorphisms May Identify a Subgroup of Breast Cancer Patients with Favorable Outcome under Bevacizumab-Based Therapy—A Message from COMET, a French Unicancer Multicentric Study. Pharmaceuticals. 13(11). 414–414. 7 indexed citations

Lerebours, Florence, Marina Pulido, Emmanuelle Fourme, et al.. (2020). Predictive factors of 5-year relapse-free survival in HR+/HER2- breast cancer patients treated with neoadjuvant endocrine therapy: pooled analysis of two phase 2 trials. British Journal of Cancer. 122(6). 759–765. 13 indexed citations

Frenel, Jean‐Sébastien, Florence Dalenc, Barbara Pistilli, et al.. (2020). 304P ESR1 mutations and outcomes in BRCA1/2 or PALB2 germline mutation carriers receiving first line aromatase inhibitor + palbociclib (AI+P) for metastatic breast cancer (MBC) in the PADA-1 trial. Annals of Oncology. 31. S364–S364. 14 indexed citations

Tran-Dien, Alicia, Jérôme Lemonnier, Florence Dalenc, et al.. (2019). Association between FGFR1 copy numbers, MAP3K1 mutations, and survival in axillary node-positive, hormone receptor-positive, and HER2-negative early breast cancer in the PACS04 and METABRIC studies. Breast Cancer Research and Treatment. 179(2). 387–401. 10 indexed citations

10.

Huober, Jens, Karin Ribi, Patrik Weder, et al.. (2019). Pertuzumab (P) + trastuzumab (T) with or without chemotherapy both followed by T-DM1 in case of progression in patients with HER2-positive metastatic breast cancer (MBC) - The PERNETTA trial (SAKK 22/10), a randomized open label phase II study (SAKK, UNICANCER, BOOG). Annals of Oncology. 30. iii47–iii47. 4 indexed citations

11.

Lovinfosse, Pierre, Caroline Rousseau, Jean‐Yves Pierga, et al.. (2019). Dual time point [18F]FLT-PET for differentiating proliferating tissues vs non-proliferating tissues. EJNMMI Research. 9(1). 109–109. 2 indexed citations

12.

Guillon, Jordan, Coralie Petit, Marie Moreau, et al.. (2019). Regulation of senescence escape by TSP1 and CD47 following chemotherapy treatment. Cell Death and Disease. 10(3). 199–199. 65 indexed citations

13.

Gonçalvès, Anthony, Jean‐Yves Pierga, Jean-Marc Ferrero, et al.. (2015). UNICANCER-PEGASE 07 study: a randomized phase III trial evaluating postoperative docetaxel–5FU regimen after neoadjuvant dose-intense chemotherapy for treatment of inflammatory breast cancer. Annals of Oncology. 26(8). 1692–1697. 14 indexed citations

14.

Roca, Lise, Véronique Dièras, Henri Roché, et al.. (2013). Correlation of HER2, FCGR2A, and FCGR3A gene polymorphisms with trastuzumab related cardiac toxicity and efficacy in a subgroup of patients from UNICANCER-PACS04 trial. Breast Cancer Research and Treatment. 139(3). 789–800. 48 indexed citations

15.

Debiais, Françoise, G. Lefèvre, Jérôme Lemonnier, et al.. (2004). Fibroblast growth factor-2 induces osteoblast survival through a phosphatidylinositol 3-kinase-dependent, -β-catenin-independent signaling pathway. Experimental Cell Research. 297(1). 235–246. 67 indexed citations

16.

Kaabeche, Karim, Jérôme Lemonnier, Sandrine Le Mée, Joseph Caverzasio, & Pierre J. Marie. (2004). Cbl-mediated Degradation of Lyn and Fyn Induced by Constitutive Fibroblast Growth Factor Receptor-2 Activation Supports Osteoblast Differentiation. Journal of Biological Chemistry. 279(35). 36259–36267. 74 indexed citations

17.

Lemonnier, Jérôme, Chafik Ghayor, Jérôme Guicheux, & Joseph Caverzasio. (2003). Protein Kinase C-independent Activation of Protein Kinase D Is Involved in BMP-2-induced Activation of Stress Mitogen-activated Protein Kinases JNK and p38 and Osteoblastic Cell Differentiation. Journal of Biological Chemistry. 279(1). 259–264. 117 indexed citations

18.

Haÿ, Eric, Jérôme Lemonnier, Olivia Fromigué, & Pierre J. Marie. (2001). Bone Morphogenetic Protein-2 Promotes Osteoblast Apoptosis through a Smad-independent, Protein Kinase C-dependent Signaling Pathway. Journal of Biological Chemistry. 276(31). 29028–29036. 148 indexed citations

19.

Lemonnier, Jérôme, Philippe Delannoy, M. Hott, et al.. (2000). The Ser252Trp Fibroblast Growth Factor Receptor-2 (FGFR-2) Mutation Induces PKC-Independent Downregulation of FGFR-2 Associated with Premature Calvaria Osteoblast Differentiation. Experimental Cell Research. 256(1). 158–167. 67 indexed citations

20.

Lemonnier, Jérôme, et al.. (1964). THYMOLIPOME M'EDIASTINAL.. Archives Des Maladies Du Coeur Et Des Vaisseaux. 57. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact